Proton pump inhibitors, beta-blockers, antimetabolites linked to infection with antibiotic-resistant bacteria<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 19, 2021 (HealthDay News) — Exposure to commonly prescribed non-antimicrobial drugs is associated with infection with antibiotic-resistant Enterobacteriaceae, according to a study presented at the annual European Congress of Clinical Microbiology and Infectious Diseases, held virtually from July 9 to 12.<\/p>\n
Meital Elbaz, M.D., from the Tel Aviv Medical Center in Israel, and colleagues used electronic health record data to assess exposure to 22 non-antimicrobial drug classes prior to hospital admission for 1,807 patients admitted at a tertiary-level academic hospital (Jan. 1, 2017, to April 18, 2019) with a diagnosis of upper urinary tract infection and positive urine or blood culture growing Enterobacteriaceae.<\/p>\n
The researchers identified drug-resistant organisms (DROs) in 52.2 percent of episodes, while multi-DROs (resistant to three or more classes) were identified in 23.8 percent of episodes. Exposure to seven drug classes was associated with DROs, and three drug classes (proton pump inhibitors [PPIs], beta-blockers, and antimetabolites) were significantly associated with multi-DROs. There was a significant association observed between exposure to beta-blockers, PPIs, and antimetabolites and resistance to third-generation cephalosporins, trimethoprim-sulfamethoxazole, and fluoroquinolones, when accounting for antimicrobial drug exposure and previous hospitalization. <\/p>\n
“We urgently need larger studies with more drug classes to confirm the discovery and to clarify the biological link between common prescription drugs and antibiotic resistance,” Elbaz said in a statement.<\/p>\n